A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pf 06650833 Delivered in Multiple Formulations in Healthy Subjects Under Fasted and Fed Conditions
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2015
At a glance
- Drugs PF 6650833 (Primary) ; PF 6650833 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Pfizer
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 13 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.